2008-2016年经皮冠状动脉介入治疗后抗血小板初治患者中血小板二磷酸腺苷P2Y12受体抑制剂使用趋势与依从性
该回顾性队列研究利用美国UnitedHealthcare行政索赔数据,纳入2008年1月1日至2016年12月1日期间因PCI住院、且PCI前90天未使用P2Y12抑制剂的18-64岁患者共55 340例(女性12 754例,占23.0%;平均年龄54.4岁,SD 7.1)。2008年93.6%患者出院30天内取氯吡格雷处方、6.4%未取P2Y12抑制剂;2016年氯吡格雷44.0%、普拉格雷或替格瑞洛36.9%、未取药19.1%。药物洗脱支架患者6个月平均MPR:氯吡格雷0.85、普拉格雷0.79、替格瑞洛0.76(P<.001);12个月分别为0.76、0.71、0.68(P<.001),新药自付费用更高。
要点
- 2008年至2016年PCI术后出院30天内未取P2Y12抑制剂处方的比例从6.4%升至19.1%,同期普拉格雷/替格瑞洛取药比例升至36.9%。
- 药物洗脱支架患者6个月平均MPR:氯吡格雷0.85 vs 普拉格雷0.79 vs 替格瑞洛0.76(P<.001),新药依从性较低。
- 12个月平均MPR:氯吡格雷0.76 vs 普拉格雷0.71 vs 替格瑞洛0.68(P<.001),依从性随时间进一步下降。
- 6个月自付费用:氯吡格雷132美元 vs 普拉格雷287美元 vs 替格瑞洛265美元(P<.001);12个月分别为251、556、557美元(P<.001)。
- 作者认为,更新、更昂贵的P2Y12抑制剂的引入与这些治疗依从性降低相关。
适用人群与场景
- 2008年1月1日至2016年12月1日期间因PCI住院、年龄18-64岁、PCI前90天内未接受P2Y12抑制剂治疗、纳入美国UnitedHealthcare行政索赔数据库的患者。
研究设计与关键结果
- 研究类型:回顾性队列研究,使用美国一家大型全国性保险公司(UnitedHealthcare)的行政索赔数据;样本量55 340例,女性12 754例(23.0%),平均年龄54.4岁(SD 7.1)。
- 2008年7667例(93.6%)出院30天内取氯吡格雷处方,521例(6.4%)未取P2Y12抑制剂处方;2016年2406例(44.0%)取氯吡格雷、2015例(36.9%)取普拉格雷或替格瑞洛、1045例(19.1%)未取P2Y12抑制剂处方。
- 药物洗脱支架患者6个月平均MPR:氯吡格雷0.85(IQR 0.82-1.00)、普拉格雷0.79(IQR 0.66-1.00)、替格瑞洛0.76(IQR 0.66-0.98),P<.001。
- 药物洗脱支架患者6个月平均自付费用:氯吡格雷132美元(IQR 47-203)、普拉格雷287美元(IQR 152-389)、替格瑞洛265美元(IQR 53-387),P<.001。
- 12个月平均MPR:氯吡格雷0.76(IQR 0.58-0.99)、普拉格雷0.71(IQR 0.49-0.98)、替格瑞洛0.68(IQR 0.41-0.94),P<.001。
- 12个月平均总自付费用:氯吡格雷251美元(IQR 100-371)、普拉格雷556美元(IQR 348-730)、替格瑞洛557美元(IQR 233-744),P<.001。
证据类型、等级与局限
- 证据类型:回顾性队列研究(行政索赔数据分析)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,2008年至2016年间普拉格雷和替格瑞洛使用增加伴随出院30天内未取P2Y12抑制剂处方增加。
- 作者认为,与氯吡格雷相比,普拉格雷和替格瑞洛在PCI后一年内患者费用更高、依从性更低。
- 作者认为,更新、更昂贵的P2Y12抑制剂的引入与这些治疗依从性降低相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Current guidelines recommend prasugrel hydrochloride and ticagrelor hydrochloride as preferred therapies for patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI). However, it is not well known how frequently these newer agents are being used in clinical practice or how adherence varies among the platelet adenosine diphosphate P2Y12 receptor (P2Y12) inhibitors.
OBJECTIVES: To determine trends in use of the different P2Y12 inhibitors in patients who underwent PCI from 2008 to 2016 in a large cohort of commercially insured patients and differences in patient adherence and costs among the P2Y12 inhibitors.
DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study used administrative claims from a large US national insurer (ie, UnitedHealthcare) from January 1, 2008, to December 1, 2016, comprising patients aged 18 to 64 years hospitalized for PCI who had not received a P2Y12 inhibitor for 90 days preceding PCI. The P2Y12 inhibitor filled within 30 days of discharge was identified from pharmacy claims.
MAIN OUTCOMES AND MEASURES: Proportion of patients filling prescriptions for P2Y12 inhibitors within 30 days of discharge by year, as well as medication possession ratios (MPRs) and total P2Y12 inhibitor copayments at 6 and 12 months for patients who received drug-eluting stents.
RESULTS: A total of 55 340 patients (12 754 [23.0%] women; mean [SD] age, 54.4 [7.1] years) who underwent PCI were included in this study. In 2008, 7667 (93.6%) patients filled a prescription for clopidogrel bisulfate and 521 (6.4%) filled no P2Y12 inhibitor prescription within 30 days of hospitalization. In 2016, 2406 (44.0%) patients filled clopidogrel prescriptions, 2015 (36.9%) filled either prasugrel or ticagrelor prescriptions, and 1045 (19.1%) patients filled no P2Y12 inhibitor prescription within 30 days of hospitalization. At 6 months, mean MPRs for patients who received a drug-eluting stent filling clopidogrel, prasugrel, and ticagrelor prescriptions were 0.85 (interquartile range [IQR], 0.82-1.00), 0.79 (IQR, 0.66-1.00), and 0.76 (IQR, 0.66-0.98) (P < .001), respectively; mean copayments for a 6 months' supply were $132 (IQR, $47-$203), $287 (IQR, $152-$389), and $265 (IQR, $53-$387) (P < .001), respectively. At 12 months, mean MPRs for clopidogrel, prasugrel, and ticagrelor were 0.76 (IQR, 0.58-0.99), 0.71 (IQR, 0.49-0.98), and 0.68 (IQR, 0.41-0.94) (P < .001), respectively; mean total copayments were $251 (IQR, $100-$371), $556 (IQR, $348-$730), and $557 (IQR, $233-$744) (P < .001), respectively.
CONCLUSIONS AND RELEVANCE: Between 2008 and 2016, increased use of prasugrel and ticagrelor was accompanied by increased nonfilling of prescriptions for P2Y12 inhibitors within 30 days of discharge. Prasugrel and ticagrelor had higher patient costs and lower adherence in the year following PCI compared with clopidogrel. The introduction of newer, more expensive P2Y12 inhibitors was associated with lower adherence to these therapies.
参考来源
- Dayoub EJ, Seigerman M, Tuteja S, et al. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016. JAMA Intern Med. 2018. PMID: 29799992. doi:10.1001/jamainternmed.2018.0783
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。